|
|
 |
 |
| |
 Printable version |
Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma |
European Journal of Dermatology. Volume 8, Number 4, 235-9, June 1998, Thérapeutique
|
 Free Article
|
Author(s) : Philippe ANDRES, Didier CUPISSOL, Bernard GUILLOT, Marie-Françoise AVRIL, Brigitte DRENO |
Summary : The anti-tumoral activity of interleukin-2 (IL-2) is well-documented. Although the response rate with this cytokine is low, it appears to be improved when associated with interferon-alpha (INF-alpha) and/or cytotoxic drugs.
Aim of this work was to study the efficacy and tolerance of an ambulatory treatment using subcutaneous, low-dose IL-2 with subcutaneous INF-alpha and chemotherapy.
We report a multicenter study of ambulatory treatment combining subcutaneous (SC) low-dose IL-2 (9 x 106 IU) with SC INF-alpha-2a (3 x 106 IU) and cisplatin (100 mg/m2) in 33 patients (13 women and 20 men, 22 to 66 years of age) with metastatic malignant melanoma. Metastases were mainly nodal (54.5%) and pulmonary (51.5%). For 81.8% of patients, this therapy constituted the first-line treatment.
The overall response rate at the end of the first maintenance course was 30.3% (3 complete responses and 7 partial responses). Adverse effects were observed in 28 patients (84.8%), but were most often minor (grade 1 or 2 on the WHO toxicity scale).
The results confirmed the good tolerance to SC IL-2 and its suitability for ambulatory therapy, as well as the potential benefit of associating IL-2 with cisplatin in the treatment of metastatic melanoma (a possibility considered in two previous studies). |
Keywords : metastatic melanoma, cisplatin, subcutaneous interleukin-2, interferon-alpha. |
|
